Table 3.
Changes in hemodynamic, blood gas parameters and organ function
| Baseline | 24 h | 72 h | p (time)a | p (interaction)b | |
|---|---|---|---|---|---|
| MAP (mmHg) | 0.083 | 0.309 | |||
| Pentaglobin (n = 10) | 80 ± 14 | 82 ± 9 | 86 ± 15 | ||
| Placebo (n = 9) | 85 ± 15 | 75 ± 17 | 89 ± 13 | ||
| HR (bpm) | 0.662 | 0.169 | |||
| Pentaglobin (n = 10) | 84 ± 23 | 85 ± 11 | 90 ± 21 | ||
| Placebo (n = 9) | 95 ± 19 | 89 ± 30 | 80 ± 25 | ||
| Norepinephrine tartrate (n, mcg/kg/min) | – | ||||
| Pentaglobin (n = 10) | 8, 0.13 [0.03–0.39] | 8, 0.12 [0.03–0.23] | 7, 0.11 [0–0.38] | 0.616 | |
| Placebo (n = 9) | 8, 0.38 [0.23–0.70] | 8, 0.50 [0.14–0.70] | 6, 0.10 [0–0.40]* | 0.004 | |
| Arterial pH | 0.110 | 0.377 | |||
| Pentaglobin (n = 10) | 7.43 ± 0.07 | 7.42 ± 0.06 | 7.45 ± 0.07 | ||
| Placebo (n = 9) | 7.45 ± 0.03 | 7.47 ± 0.05 | 7.49 ± 0.07 | ||
| PaO2/FiO2 (mmHg) | 0.875 | 0.474 | |||
| Pentaglobin (n = 10) | 300 ± 89 | 311 ± 151 | 320 ± 89 | ||
| Placebo (n = 9) | 311 ± 89 | 280 ± 74 | 262 ± 85 | ||
| ScvO2 (%) | < 0.001 | 0.053 | |||
| Pentaglobin (n = 10) | 80 ± 5 | 78 ± 10 | 72 ± 9* | ||
| Placebo (n = 9) | 79 ± 9 | 68 ± 9**# | 71 ± 7* | ||
| Base excess (mEq/L) | < 0.001 | 0.659 | |||
| Pentaglobin (n = 10) | 0.4 ± 4.9 | 2.5 ± 3.8 | 5.6 ± 4.9** | ||
| Placebo (n = 9) | 1.2 ± 4.7 | 4.0 ± 4.8 | 5.1 ± 4.4* | ||
| Arterial lactate (mmol/L) | – | ||||
| Pentaglobin (n = 10) | 1.7 [1.3–3.5] | 1.5 [1.0–2.2] | 1.9 [0.9–2.7] | 0.682 | |
| Placebo (n = 9) | 1.6 [1.0–2.2] | 1.4 [1.0–2.2] | 1.2 [1.1–1.7] | 0.755 | |
| Haemoglobin (g/dL) | 0.460 | 0.356 | |||
| Pentaglobin (n = 10) | 10.4 ± 1.5 | 10.5 ± 0.9 | 9.6 ± 0.9 | ||
| Placebo (n = 9) | 9.8 ± 1.8 | 10.1 ± 1.3 | 10.0 ± 1.1 | ||
| Platelets (*103/mmc) | 0.170 | 0.036 | |||
| Pentaglobin (n = 10) | 158 ± 98 | 141 ± 80 | 153 ± 83 | ||
| Placebo (n = 9) | 163 ± 86 | 168 ± 84 | 136 ± 67 | ||
| Creatinine (mg/dL) | 0.284 | 0.522 | |||
| Pentaglobin (n = 10) | 1.1 ± 0.7 | 1.0 ± 0.5 | 0.9 ± 0.4 | ||
| Placebo (n = 9) | 1.9 ± 1.0 | 2.1 ± 1.6 | 1.8 ± 1.2 | ||
| Bilirubin (mg/dL) | – | ||||
| Pentaglobin (n = 10) | 0.7 [0.5–1.7] | 0.8 [0.5–1.6] | 0.9 [0.5–1.7] | 0.356 | |
| Placebo (n = 9) | 1.0 [0.5–1.3] | 0.9 [0.5–2.3] | 0.7 [0.6–2.4] | 0.515 | |
| Glasgow Coma Scale | – | ||||
| Pentaglobin (n = 10) | 14 [13–15] | 15 [13–15] | 15 [11–15] | 0.999 | |
| Placebo (n = 9) | 14 [10–14] | 13 [9–14] | 12 [10–14] | 0.999 | |
| SOFA score | – | ||||
| Pentaglobin (n = 10) | 9 [7–11] | 9 [5–10] | 7 [6–8] | 0.229 | |
| Placebo (n = 9) | 10 [7–13] | 12 [6–12] | 10 [6–12] | 0.544 | |
| Propofol (mg/kg/h, n) | – | ||||
| Pentaglobin (n = 10) | 1.2 [0–2.4], 7 | 0 [0–2.6], 4 | 0 [0–2.6], 4 | 0.790 | |
| Placebo (n = 9) | 0.8 [0–1.6], 5 | 0 [0–1.1], 4 | 0 [0–1.6], 3 | 0.518 | |
| Remifentanil (mcg/kg/min, n) | – | ||||
| Pentaglobin (n = 10) | 0.08 [0.04–0.09], 8 | 0.05 [0–0.08], 7 | 0.06 [0–0.10], 7 | 0.366 | |
| Placebo (n = 9) | 0.06 [0–0.10], 8 | 0.05 [0–0.08], 7 | 0.06 [0–0.10], 7 | 0.991 | |
Data are expressed as mean ± standard deviation or median [1st–3rd quartile], as appropriate
MAP mean arterial pressure, HR heart rate, ScvO2 central venous oxygen saturation, SOFA Sequential Organ Failure Assessment
aTwo-way analysis of variance for repeated measures (testing the effect of time) or Friedman test, as appropriate
bTwo-way analysis of variance for repeated measures (testing for the interaction between time and treatment), when applicable
* p < 0.05, **p < 0.01 versus baseline, Two-way analysis of variance for repeated measures with Sidack’s post hoc test or Friedman test with Dunn’s post hoc test for multiple comparisons, as appropriate
#p < 0.05 versus Pentaglobin group, Two-way analysis of variance for repeated measures with Sidack’s post hoc test or Mann–Whitney U test, as appropriate